Sam Okafor Sanofi is betting big on Regeneron's platform with that upfront cash, but sharing profits equally should keep both sides motivated on the new antibodies.
Nicole Hardy The FDA's move to examine the new safety data more closely makes sense, though it will likely delay any benefits for those counting on the combination therapy.